Javascript must be enabled to continue!
Evaluation of Oral Mucositis Occurrence in Oncologic Patients under Antineoplastic Therapy Submitted to the Low-Level Laser Coadjuvant Therapy
View through CrossRef
Low-level laser therapy has been widely used in treating many conditions, including oral mucositis. The purpose of this study was to evaluate the occurrence of oral mucositis in patients undergoing antineoplastic therapy submitted to preventive and therapeutic treatment with low-level laser therapy. This cross-sectional study was carried out with 51 children and adolescents of both sexes with malignant neoplasias who developed oral mucositis and underwent low-level laser therapy. Data were collected on sex, age, type and degree of neoplasia, region affected, and remission time. 64.7% of the patients were male and were between 3 and 6 years of age (39.2%). Acute lymphoid leukemia was the most frequent neoplasm (37.3%). Regarding the maximum oral mucositis, grade 2 (41.2%) was predominant, with jugal mucosa (29.9%) and tongue (17.7%) being the most affected regions. The majority of cases presented lesion remission time between 4 and 7 days (44.0%). Most patients were young, male, and diagnosed with acute lymphoid leukemia. Predominance of grade 2 oral mucositis was observed, with jugal mucosa and tongue being the most affected regions, with the majority of cases presenting lesion remission time between 4 and 7 days. Low-level laser therapy has been shown to be an essential therapy in the prevention and treatment of these lesions, since it is a non-invasive and low-cost method.
Title: Evaluation of Oral Mucositis Occurrence in Oncologic Patients under Antineoplastic Therapy Submitted to the Low-Level Laser Coadjuvant Therapy
Description:
Low-level laser therapy has been widely used in treating many conditions, including oral mucositis.
The purpose of this study was to evaluate the occurrence of oral mucositis in patients undergoing antineoplastic therapy submitted to preventive and therapeutic treatment with low-level laser therapy.
This cross-sectional study was carried out with 51 children and adolescents of both sexes with malignant neoplasias who developed oral mucositis and underwent low-level laser therapy.
Data were collected on sex, age, type and degree of neoplasia, region affected, and remission time.
64.
7% of the patients were male and were between 3 and 6 years of age (39.
2%).
Acute lymphoid leukemia was the most frequent neoplasm (37.
3%).
Regarding the maximum oral mucositis, grade 2 (41.
2%) was predominant, with jugal mucosa (29.
9%) and tongue (17.
7%) being the most affected regions.
The majority of cases presented lesion remission time between 4 and 7 days (44.
0%).
Most patients were young, male, and diagnosed with acute lymphoid leukemia.
Predominance of grade 2 oral mucositis was observed, with jugal mucosa and tongue being the most affected regions, with the majority of cases presenting lesion remission time between 4 and 7 days.
Low-level laser therapy has been shown to be an essential therapy in the prevention and treatment of these lesions, since it is a non-invasive and low-cost method.
Related Results
Evaluation of oral mucositis in pediatric cancer patients in Hiwa Hospital in Sulaymaniyah city, Kurdistan Region, Iraq
Evaluation of oral mucositis in pediatric cancer patients in Hiwa Hospital in Sulaymaniyah city, Kurdistan Region, Iraq
Background and objective: Oral mucositis is caused by the destruction of the oral mucosal epithelium and suppression of its growth secondary to antineoplastic treatment in the form...
Oral Mucositis, Incidence, Risk factors, Clinical Features, Scoring, Pathophysiology and Treatment: A Review of Literature
Oral Mucositis, Incidence, Risk factors, Clinical Features, Scoring, Pathophysiology and Treatment: A Review of Literature
Cancer is a broad group of different diseases involve the unregulated cell growth in which the cells divide uncontrollably forming the malignant tumors. The management are by chemo...
Topical application of hangeshashinto (TJ-14) in the management of chemotherapy-induced oral mucositis: A preliminary study.
Topical application of hangeshashinto (TJ-14) in the management of chemotherapy-induced oral mucositis: A preliminary study.
603 Background: Oral mucositis is a common toxicity associated with cytotoxic chemotherapy used for cancer treatment and results in severe discomfort and impairs patients' ability...
THE EFFECT LOW LEVEL LASER THERAPY FOR MANAGEMENT OF RADIATION-INDUCEED MUCOSITIS
THE EFFECT LOW LEVEL LASER THERAPY FOR MANAGEMENT OF RADIATION-INDUCEED MUCOSITIS
Low-level laser therapy as a method for correcting the mucositis caused by ionizing radiation of the oral mucosa is used in clinical practice for various exposure parameters: radia...
An Impact of Coconut Oil Pulling on Oral Mucositis among Malignancy Patients
An Impact of Coconut Oil Pulling on Oral Mucositis among Malignancy Patients
Acute or chronic oral complications may develop around 400,000 patients each year during chemotherapy. Oral mucositis happens in around 40% of patients who get malignancy chemother...
Pembrolizumab and Sarcoma: A meta-analysis
Pembrolizumab and Sarcoma: A meta-analysis
Abstract
Introduction: Pembrolizumab is a monoclonal antibody that promotes antitumor immunity. This study presents a systematic review and meta-analysis of the efficacy and safety...
Evaluation of Oral Mucositis and its Risk Factors in Patients with Head and Neck Cancer Undergoing Radiotherapy Treatment
Evaluation of Oral Mucositis and its Risk Factors in Patients with Head and Neck Cancer Undergoing Radiotherapy Treatment
Introduction: Oral mucositis is a painful and debilitating condition, often observed as an acute adverse effect of antineoplastic treatment. Patient-related risk factors, as age an...
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract
Introduction
Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...

